#Reyataz

This is according to a large study of U.S. veterans.

The two-drug regimen can cure the virus in as little as eight weeks.

The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Combo treatment with fine-particle formulations of Reyataz and Norvir, plus an immune-dampener drug, greatly reduced HIV levels in mice.

A two-drug regimen of Norvir (ritonavir)Ã¢€“boosted Reyataz (atazanavir) and Epivir (lamivudine) treats HIV as well or better tha...

Research of Bristol-Myers Squibb’s BMS-955176, an HIV maturation inhibitor, has shown the antiretroviral is potent and well-tolerated.

An updated version of Viread (tenofovir) offers slightly better viral suppression and improves indicators of kidney and bone health...

Bristol-Myers Squibb’s investigational next-generation maturation inhibitor BMS-955176 demonstrated good activity against HIV when paired...

The FDA has granted a breakthrough designation to Bristol-Myers Squibb’s investigational HIV attachment inhibitor BMS-663068.

Various HIV antiretrovirals are linked to a raised risk of cardiovascular problems, although the overall risk of such an outcome is still low.

A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antir...

People with HIV who start treatment with Truvada post similar fat gains whether they pair the tablet with Isentress or protease inhibitors.

People with HIV may experience body fat gains as a consequence of the virus rather than antiretrovirals.

People with HIV who take Viread, Norvir, Reyataz or Norvir-boosted Kaletra are at increasing risk of kidney disease over time.

Given to treatment-experienced people with HIV, the attachment inhibitor BMS-663068 (fostemsavir) demonstrated potentcy in the range of...